본문 바로가기
KERD
논문KCI 등재

Effects of Statins for Primary Prevention in the Elderly: Recent Evidence

이상학|김규
한국지질동맥경화학회 (The Korean Society of Lipidology and Atherosclerosis)|2020.01|지질·동맥경화학회지 (Journal of Lipid and Atherosclerosis)|제9권 제1호|pp. 1-7|DOI 10.12997/jla.2020.9.1.1

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ElderlyCardiovascular diseasesStatins

초록

The number of the elderly individuals is steeply increasing, and their absolute cardiovascular risk is higher than that of younger age groups. However, very few statin trials have included elderly patients alone. Recently, we published the SCOPE-75 study, which analyzed the effect of statins for primary prevention in elderly Koreans (>75 years). In this study, statin users showed significantly fewer cardiovascular events and a lower all-cause mortality rate, supporting more active use of statins in this population. In the current review, we further compare and discuss similar studies reported in the past decades and in recent years.

Abstract

The number of the elderly individuals is steeply increasing, and their absolute cardiovascular risk is higher than that of younger age groups. However, very few statin trials have included elderly patients alone. Recently, we published the SCOPE-75 study, which analyzed the effect of statins for primary prevention in elderly Koreans (>75 years). In this study, statin users showed significantly fewer cardiovascular events and a lower all-cause mortality rate, supporting more active use of statins in this population. In the current review, we further compare and discuss similar studies reported in the past decades and in recent years.

참고문헌 (26)

  1. Writing Group Members, "Heart disease and stroke statistics-2016 update : a report from the American Heart Association", Circulation, 133, pp.e38~e360 (2016)
  2. Marrugat J, "Acute myocardial infarction population incidence and in-hospital management factors associated to 28-day case-fatality in the 65 year and older", Eur J Epidemiol, 19, pp.231~237 (2004)
  3. Rapsomaniki E, "Using big data from health records from four countries to evaluate chronic disease outcomes : a study in 114 364 survivors of myocardial infarction", Eur Heart J Qual Care Clin Outcomes, 2, pp.172~183 (2016)
  4. Herrera AP, "Disparate inclusion of older adults in clinical trials : priorities and opportunities for policy and practice change", Am J Public Health, 100(Suppl 1), pp.S105~S112 (2010)
  5. Heiat A, "Representation of the elderly, women, and minorities in heart failure clinical trials", Arch Intern Med, 162, pp.1682~1688 (2002)
  6. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
  7. Mach F, "ESC", EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
  8. 이은정, "2018 Guidelines for the management of dyslipidemia", The Korean Journal of Internal Medicine, 34(4), pp.723~771 (2019), 대한내과학회[DOI]
  9. Rich MW, "Knowledge gaps in cardiovascular care of the older adult population : a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society", J Am Coll Cardiol, 67, pp.2419~2440 (2016)
  10. Kim K, "Statin and clinical outcomes of primary prevention in individuals aged >75 years : The SCOPE-75 study", Atherosclerosis, 284, pp.31~36 (2019)
  11. Taylor FC, "Statin therapy for primary prevention of cardiovascular disease", JAMA, 310, pp.2451~2452 (2013)
  12. Nakamura H, "Primary prevention of cardiovascular disease with pravastatin in Japan(MEGA Study) : a prospective randomised controlled trial", Lancet, 368, pp.1155~1163 (2006)
  13. Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
  14. Glynn RJ, "Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels : exploratory analysis of a randomized trial", Ann Intern Med, 152, pp.488~496 (2010)
  15. ALLHAT Officers, "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT-LLT)", JAMA, 288, pp.2998~3007 (2002)
  16. Han BH, "Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults : the ALLHAT-LLT randomized clinical trial", JAMA Intern Med, 177, pp.955~965 (2017)
  17. Shepherd J, "Pravastatin in elderly individuals at risk of vascular disease(PROSPER) : a randomised controlled trial", Lancet, 360, pp.1623~1630 (2002)
  18. Savarese G, "Benefits of statins in elderly subjects without established cardiovascular disease : a meta-analysis", J Am Coll Cardiol, 62, pp.2090~2099 (2013)
  19. Ridker PM, "Primary prevention with statin therapy in the elderly : new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials", Circulation, 135, pp.1979~1981 (2017)
  20. Cholesterol Treatment Trialists' Collaboration, "Efficacy and safety of statin therapy in older people : a meta-analysis of individual participant data from 28 randomised controlled trials", Lancet, 393, pp.407~415 (2019)
  21. Strandberg TE, "Role of statin therapy in primary prevention of cardiovascular disease in elderly patients", Curr Atheroscler Rep, 21, pp.28~ (2019)
  22. Ramos R, "Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes : retrospective cohort study", BMJ, 362, pp.k3359~ (2018)
  23. Bezin J, "Real-life benefits of statins for cardiovascular prevention in elderly subjects : a population-based cohort study", Am J Med, 132, pp.740~748 (2019)
  24. Jun JE, "Statins for primary prevention in adults aged 75 years and older : a nationwide population-based case-control study", Atherosclerosis, 283, pp.28~34 (2019)
  25. Zoungas S, "Statins in the elderly : an answered question?", Curr Opin Cardiol, 29, pp.372~380 (2014)
  26. Rabar S, "Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease : summary of updated NICE guidance", BMJ, 349, pp.g4356~ (2014)

관련 논문AI추천

스타틴이 총 사망률에 미치는 영향배재현대한내과학회 · 대한내과학회지2023 · 제98권 제1호Reassessment of Inclusion Criteria in the 2013 the American College of Cardiology and the American Heart Association Cholesterol Guidelines for Cardiovascular Disease Prevention김종헌, 김형섭, 이종원, 임현선대한신경과학회 · Journal of Clinical Neurology2021 · 제17권 제1호국내 성인환자에서 죽상동맥경화성 심혈관질환 위험도와 스타틴 처방 현황김종윤, 유기연한국임상약학회 · 한국임상약학회지2021 · 제31권 제3호Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin RegistryChang-Wook Nam, Deug Young Nah, Han Joon Bae, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, Jae-Kean Ryu, Kwon-Bae Kim, Seongwook Han, Seung-Ho Hur, Yoon-Nyun Kim, Yun-Kyeong Cho대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제2호Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol권현철, 김두일, 김종진, 김효수, 나승운, 박종선, 성인환, 승기배, 심두선, 안태훈, 오석규, 윤정한, 정명호, 조명찬, 주승재, 차광수, 채성철, 채제건, 최동주, 허승호, 황진용한국지질동맥경화학회 · 지질·동맥경화학회지2019 · 제8권 제2호스타틴 치료 시 부작용에 대한 전략박종남, 최희정대한가정의학회 · Korean Journal of Family Medicine2004 · 제25권 제10호

이 간행물의 다른 논문 (15건)

mTOR-coordinated Post-Transcriptional Gene Regulations: from Fundamental to Pathogenic Insights용정식, Hsin-Sung Yehpp. 8-22Sphingolipid Mediators of Myocardial PathologyAnna Kovilakath, L. Ashley Cowartpp. 23-49Ceramides: Nutrient Signals that Drive HepatosteatosisScott A. Summerspp. 50-65CD36 (SR-B2) as a Target to Treat Lipid Overload-Induced Cardiac DysfunctionJan F.C. Glatz, Joost J.F.P. Luiken, Miranda Nabbenpp. 66-78Cellular Senescence in Arterial DiseasesTohru Minamino, Ippei Shimizupp. 79-91
원문 보기